Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity.

IF 3.2 Q2 Pharmacology, Toxicology and Pharmaceutics

Current clinical pharmacology Pub Date : 2019-01-01 DOI:10.2174/1574884713666181112125714

Sapan K Behera, Saibal Das, Kavadichanda G Chengappa, Alphienes S Xavier, Sandhiya Selvarajan

{"title":"Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity.","authors":"Sapan K Behera, Saibal Das, Kavadichanda G Chengappa, Alphienes S Xavier, Sandhiya Selvarajan","doi":"10.2174/1574884713666181112125714","DOIUrl":null,"url":null,"abstract":"Aim: Multiple drug intolerance syndrome (MDIS) is a unique clinical entity distinct from other drug hypersensitivity syndromes. The aim of this review was to critically appraise the various aspects of MDIS.Methods: A review was conducted to search for the causes, mechanism, clinical features, and management of MDIS.Results: The most common cause of MDIS is antibiotics followed by non-steroidal antiinflammatory drugs (NSAIDs). Although some non-specific immunological mechanisms are involved, the immunological tests for MDIS are negative. Rashes, gastrointestinal reflux, headache, cough, muscle ache, fever, dermatitis, hypertension, and psychiatric symptoms are the usual manifestations. Treatment is mostly symptomatic with the withdrawal of the offending drug. Drug rechallenges and desensitization may be required for the management of this syndrome.Conclusion: MDIS occurs by a nonimmune mechanism which requires a prompt withdrawal of the offending drug(s), and in some cases may require drug re-challenge and desensitization.","PeriodicalId":10746,"journal":{"name":"Current clinical pharmacology","volume":"14 2","pages":"84-90"},"PeriodicalIF":3.2000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574884713666181112125714","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current clinical pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574884713666181112125714","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 3

Abstract

Aim: Multiple drug intolerance syndrome (MDIS) is a unique clinical entity distinct from other drug hypersensitivity syndromes. The aim of this review was to critically appraise the various aspects of MDIS.

Methods: A review was conducted to search for the causes, mechanism, clinical features, and management of MDIS.

Results: The most common cause of MDIS is antibiotics followed by non-steroidal antiinflammatory drugs (NSAIDs). Although some non-specific immunological mechanisms are involved, the immunological tests for MDIS are negative. Rashes, gastrointestinal reflux, headache, cough, muscle ache, fever, dermatitis, hypertension, and psychiatric symptoms are the usual manifestations. Treatment is mostly symptomatic with the withdrawal of the offending drug. Drug rechallenges and desensitization may be required for the management of this syndrome.

Conclusion: MDIS occurs by a nonimmune mechanism which requires a prompt withdrawal of the offending drug(s), and in some cases may require drug re-challenge and desensitization.

Abstract Image

查看原文本刊更多论文

多种药物不耐受综合征:一个被低估的独特临床实体。

目的:多种药物不耐受综合征(MDIS)是一种不同于其他药物过敏综合征的独特临床症状。本综述的目的是对MDIS的各个方面进行批判性评价。方法:回顾性分析MDIS的病因、发病机制、临床特点及处理方法。结果:导致MDIS的最常见原因是抗生素，其次是非甾体类抗炎药(NSAIDs)。虽然涉及一些非特异性免疫机制，但MDIS的免疫试验呈阴性。皮疹、胃肠道反流、头痛、咳嗽、肌肉疼痛、发热、皮炎、高血压和精神症状是常见的表现。治疗主要是症状性的，需要停药。药物再挑战和脱敏可能需要对这种综合征的管理。结论:MDIS是通过非免疫机制发生的，需要迅速停药，在某些情况下可能需要药物再次挑战和脱敏。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current clinical pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

3.60

自引率

0.00%

发文量

期刊介绍： Current Clinical Pharmacology publishes frontier reviews on all the latest advances in clinical pharmacology. The journal"s aim is to publish the highest quality review articles in the field. Topics covered include: pharmacokinetics; therapeutic trials; adverse drug reactions; drug interactions; drug metabolism; pharmacoepidemiology; and drug development. The journal is essential reading for all researchers in clinical pharmacology.